<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: We retrospectively evaluated our results with the BioValsalva Conduit (Vascutek Terumo, Renfrewshire Scotland), a stentless porcine valve incorporated in a 3-layered prosthetic graft </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: From July 2008 through April 2011, 102 patients with a mean age of 70.9 Â± 7.3 years underwent aortic root replacement with a BioValsalva conduit </plain></SENT>
<SENT sid="2" pm="."><plain>The indication for surgery was aneurysmal <z:e sem="disease" ids="C0003493" disease_type="Disease or Syndrome" abbrv="">disease of the aorta</z:e> in 81 patients (79.4%), aortic valve <z:hpo ids='HP_0100584'>endocarditis</z:hpo> in 15 patients (14.7%), <z:hpo ids='HP_0011009'>acute</z:hpo> type A <z:hpo ids='HP_0002647'>aortic dissection</z:hpo> in 4 patients (3.9%), and other causes in 2 patients (2.0%) </plain></SENT>
<SENT sid="3" pm="."><plain>In 26 patients (25.5%), the intervention was a reoperation </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Overall hospital mortality was 4.9% (n = 5; 95% confidence limit [CL], 1.6%-11.1%) </plain></SENT>
<SENT sid="5" pm="."><plain>Cause of <z:hpo ids='HP_0011420'>death</z:hpo> was <z:hpo ids='HP_0001635'>cardiac failure</z:hpo> in 2 patients, multiple organ or <z:hpo ids='HP_0000083'>renal failure</z:hpo> in 2 patients, and tamponade in 1 patient </plain></SENT>
<SENT sid="6" pm="."><plain>Mean follow-up was 8.1 months </plain></SENT>
<SENT sid="7" pm="."><plain>During follow-up, 3 <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred (3.1%) because of <z:e sem="disease" ids="C0025064" disease_type="Disease or Syndrome" abbrv="">mediastinitis</z:e>, <z:mp ids='MP_0004120'>cardiac ischemia</z:mp>, and <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The overall survival at 3 and 12 months was 95.9% (95% CL, 92.0% -99.9%) and 92.1% (95% CL, 85.7% -98.9%) respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Three patients (3.1%) had new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:hpo ids='HP_0100584'>endocarditis</z:hpo> of the BioValsalva conduit; 2 of these patients required reoperation and 1 patient received antibiotic treatment only </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Retrospective analysis of the BioValsalva conduit for aortic root replacement in more than 100 consecutive patients demonstrated satisfactory initial results, with low mortality and acceptable low morbidity rates </plain></SENT>
<SENT sid="11" pm="."><plain>Follow-up is mandatory and long-term results are to be awaited </plain></SENT>
</text></document>